Medical Editor: John P. Cunha, DO, FACOEP
What Is Rhopressa?
What Are Side Effects of Rhopressa?
Common side effects of Rhopressa include:
- eye redness,
- corneal abnormalities,
- instillation site pain,
- and burst blood vessels in the eye.
Dosage for Rhopressa
The dose of Rhopressa is one drop into the affected eye(s) once daily in the evening.
What Drugs, Substances, or Supplements Interact with Rhopressa?
Rhopressa may interact with other drugs. Tell your doctor all medications and supplements you use.
Rhopressa During Pregnancy or Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant before using Rhopressa; it is unknown if it would affect a fetus. It is unknown if Rhopressa passes into breast milk. Consult your doctor before breastfeeding.
Our Rhopressa (netarsudil ophthalmic solution) 0.02%, for Topical Ophthalmic Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
The most common ocular adverse reaction observed in controlled clinical studies with RHOPRESSA dosed once daily was conjunctival hyperemia which was reported in 53% of patients. Other common (approximately 20%) ocular adverse reactions reported were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients.
Corneal verticillata occurred in approximately 20% of the patients in controlled clinical studies. The corneal verticillata seen in RHOPRESSA-treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes in patients. Most corneal verticillata resolved upon discontinuation of treatment.
Read the entire FDA prescribing information for Rhopressa (Netarsudil Topical Ophthalmic Use)
© Rhopressa Patient Information is supplied by Cerner Multum, Inc. and Rhopressa Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.
Health Solutions From Our Sponsors